Literature DB >> 17406800

[Relevance of bisphosphonate long-term therapy in radiation therapy of endosteal jaw metastases].

Knut A Grötz1, Christian Walter, Christian Küttner, Bilal Al-Nawas.   

Abstract

BACKGROUND AND
PURPOSE: Bisphosphonates are used in the treatment of bone metastasis and malignant myeloma. They have been associated with osteonecrosis of the jaw (ONJ) since the year 2003. Etiology and pathogenesis of this clinical problem are not clear. The high rate of newly diagnosed cases is alarming. Based on the collective of two departments of oral and maxillofacial surgery, the results of therapy in the coincidence of systemic bisphosphonate treatment and local radiotherapy (RT) are analyzed. PATIENTS AND METHODS: In the course of 33 months (01/2003-09/2005), 63 synchronic or metachronic ONJs were seen in 42 patients as newly diagnosed episodes. Three of the 42 patients had an RT of jaw metastasis.
RESULTS: Only one patient was followed over the whole treatment period. Under RT she developed a therapy-refractory ONJ similar to osteoradionecrosis at a dose of 40 Gy. She required a wide segmental osteotomy of the mandible resulting in a total loss of masticatory function. In 39 patients with 60 ONJs without RT not a single segmental resection of the mandible was necessary.
CONCLUSION: Local RT in bisphosphonate long-term therapy seems to be a high risk constellation. As long as the pathogenesis of bisphosphonate-associated ONJ is unclear, patients subjected to RT of the head-and-neck area should be examined and dental findings should be treated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17406800     DOI: 10.1007/s00066-007-1666-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  7 in total

Review 1.  Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies.

Authors:  Vassilios Vassiliou; Nikolaos Tselis; Dimitrios Kardamakis
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

2.  Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients.

Authors:  Christian Walter; Bilal Al-Nawas; Norbert Frickhofen; Heinold Gamm; Joachim Beck; Laura Reinsch; Christina Blum; Knut A Grötz; Wilfried Wagner
Journal:  Head Face Med       Date:  2010-07-08       Impact factor: 2.151

Review 3.  [Osteonecrosis of the jaws by long term therapy with bisphosphonates].

Authors:  Jörn-Uwe Piesold; Bilal Al-Nawas; Knut A Grötz
Journal:  Mund Kiefer Gesichtschir       Date:  2006-09

4.  Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.

Authors:  Philipp Stockmann; Fabian M Hinkmann; Michael M Lell; Matthias Fenner; Eleftherios Vairaktaris; Friedrich-Wilhelm Neukam; Emeka Nkenke
Journal:  Clin Oral Investig       Date:  2009-06-10       Impact factor: 3.573

5.  DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC).

Authors:  Rainer Souchon; Frederik Wenz; Felix Sedlmayer; Wilfried Budach; Jürgen Dunst; Petra Feyer; Wulf Haase; Wolfgang Harms; Marie-Luise Sautter-Bihl; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2009-08-28       Impact factor: 3.621

Review 6.  [Systemic therapy approaches in patients with bone metastases of urogenital malignancies].

Authors:  F Finter; F M Mottaghy; R Kuefer; R E Hautmann; L Rinnab
Journal:  Urologe A       Date:  2007-08       Impact factor: 0.639

7.  Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw.

Authors:  X Wei; S Pushalkar; C Estilo; C Wong; A Farooki; M Fornier; G Bohle; J Huryn; Y Li; S Doty; D Saxena
Journal:  Oral Dis       Date:  2012-03-23       Impact factor: 3.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.